CD44 and hepatocellular carcinoma: Glypican‐3 (GPC3), a heparan sulfate proteoglycan anchored to the cell membrane, has become a pivotal target for HCC therapy due to its overexpression in more than 70% of HCC tissues.[4] GPC3 is highly expressed compared to alpha‐fetoprotein (AFP) and is not present in benign hepatic lesions or normal liver parenchyma, rendering it a more specific HCC biomarker.